Argonaut Manufacturing Services
Series A in 2024
Argonaut specializes in contract manufacturing for biopharmaceutical, diagnostics, and life science companies. Its services include high-yield aseptic fill/finish, reagent formulation, filling, kitting, lyophilization, and analytical support, catering to diverse outsourcing needs.
Cell Microsystems
Series B in 2023
Cell Microsystems, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, that focuses on developing, manufacturing, and commercializing innovative tools for single-cell biology. Founded in 2010, the company is known for its proprietary CellRaft™ Technology, which allows for the efficient sorting and isolation of single cells under standard culture conditions, preserving their unperturbed phenotypes and high viability. This technology is complemented by an automated imaging platform, enabling real-time selection and tracking of individual cells throughout imaging, collection, and downstream analysis. By facilitating single-cell isolation from small and valuable samples, Cell Microsystems provides scalable solutions that make advanced cell separation technology accessible to laboratories, enhancing the capabilities of researchers in single-cell research and genomics.
Panome Bio
Venture Round in 2023
Founded in 2022, Panome Bio specializes in biomarker discovery through its metabolomics platform. It offers services including untargeted analysis and proprietary computational methods for metabolomics, lipidomics, and proteomics screening.
Emerging Therapy Solutions
Venture Round in 2022
Emerging Therapy Solutions, Inc. is a company based in Bloomington, Minnesota, that specializes in the outsourced management of cell and gene therapy treatments for healthcare payers. Founded in 2018, it offers a comprehensive range of services including patient management, data collection, analysis, reporting, and claims administration. The company focuses on developing proprietary algorithms that enable effective targeting and segmentation of rare conditions. By providing a predictive intelligence platform, Emerging Therapy Solutions aims to simplify the management of complex therapy treatments, thereby enhancing the efficiency of healthcare providers in managing these advanced therapies.
Mosaic Biosciences
Venture Round in 2022
Founded in 2009, Mosaic Biosciences is a Boulder, Colorado-based company specializing in biomaterial technology for tissue engineering applications. Its platform enables various medical uses such as drug delivery, regenerative medicine, stem cell therapies, and sealants/adhesion barriers.
Excellos
Funding Round in 2022
Excellos specializes in the development and manufacturing of cell and gene therapies. It offers contract development and manufacturing services for various therapeutic modalities such as CAR-T, TIL, and immunotherapy. The company focuses on providing cGMP cellular products and services to scientists and physicians working with advanced therapies.
Cell Microsystems
Venture Round in 2021
Cell Microsystems, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, that focuses on developing, manufacturing, and commercializing innovative tools for single-cell biology. Founded in 2010, the company is known for its proprietary CellRaft™ Technology, which allows for the efficient sorting and isolation of single cells under standard culture conditions, preserving their unperturbed phenotypes and high viability. This technology is complemented by an automated imaging platform, enabling real-time selection and tracking of individual cells throughout imaging, collection, and downstream analysis. By facilitating single-cell isolation from small and valuable samples, Cell Microsystems provides scalable solutions that make advanced cell separation technology accessible to laboratories, enhancing the capabilities of researchers in single-cell research and genomics.
Carterra
Venture Round in 2020
Carterra, Inc. is a biotechnology company specializing in label-free biomolecular interaction analysis solutions. Founded in 2005 and headquartered in Salt Lake City, Utah, Carterra offers a range of products and services that facilitate multiplexing on planar array surfaces. Its flagship technologies include the MultipleX 96, an array-based surface plasmon resonance (SPR) imaging system, and the Continuous Flow Microspotter (CFM), a microarray printer that employs flow for efficient sample deposition. The company's offerings extend to contract research services, which cover high-throughput epitope binning and mapping, first-pass kinetics, and assay development. Additionally, Carterra provides a variety of supporting solutions, such as maintenance solutions, kits, and running buffers. These products are utilized in various applications, including kinetics software, epitope software, and antibody format development. Carterra also operates additional offices in Dublin, California; Andover, Massachusetts; and Munich, Germany, and sells its products through distributors in China and Japan, as well as online.
Nivagen Pharmaceuticals
Venture Round in 2020
Nivagen Pharmaceuticals develops, acquires, and sells generic prescription drugs and over-the-counter products for the North American market. It distributes through chain drug stores, regional wholesalers, mass merchandisers, hospitals, group purchasing organizations, mail-order pharmacies, and other buying groups. The company pursues high-quality, affordable products through partnerships with FDA-approved manufacturing facilities worldwide and via global alliances with FDA-qualified manufacturers to enable launches and deliver cost savings across the supply chain. Founded in 2009 and based in Sacramento, California, Nivagen focuses on difficult-to-formulate generic and branded prescription drugs, offering development, co-development, acquisition, in-licensing, sales, and marketing to support product introductions.
Carterra
Venture Round in 2020
Carterra, Inc. is a biotechnology company specializing in label-free biomolecular interaction analysis solutions. Founded in 2005 and headquartered in Salt Lake City, Utah, Carterra offers a range of products and services that facilitate multiplexing on planar array surfaces. Its flagship technologies include the MultipleX 96, an array-based surface plasmon resonance (SPR) imaging system, and the Continuous Flow Microspotter (CFM), a microarray printer that employs flow for efficient sample deposition. The company's offerings extend to contract research services, which cover high-throughput epitope binning and mapping, first-pass kinetics, and assay development. Additionally, Carterra provides a variety of supporting solutions, such as maintenance solutions, kits, and running buffers. These products are utilized in various applications, including kinetics software, epitope software, and antibody format development. Carterra also operates additional offices in Dublin, California; Andover, Massachusetts; and Munich, Germany, and sells its products through distributors in China and Japan, as well as online.
Akoya Biosciences
Series D in 2019
Akoya Biosciences is a life sciences company specializing in spatial biology. It provides end-to-end solutions for high-parameter tissue analysis across discovery, translational research, and clinical applications, supporting the development of more precise therapies in immuno-oncology and other drug areas. The company offers two main platforms: PhenoCycler (formerly CODEX), a benchtop system capable of quantifying more than 40 biomarkers for biomarker discovery, and PhenoImager (formerly Phenoptics), an end-to-end multiplexed immunofluorescence platform designed for robust, high-throughput translational research and clinical trials. Its offerings include reagents, software, and services to enable tissue analysis and spatial phenotyping across the research continuum.
Specific Diagnostics
Venture Round in 2019
Specific Diagnostics LLC, established in 2011 and based in West Palm Beach, Florida, specializes in developing innovative solutions for bacterial detection, identification, and antibiotic susceptibility testing. The company's flagship product is the Specific Reveal system, which employs patented small molecule sensor technology to deliver rapid and cost-effective antibiotic susceptibility results, enabling clinics to tailor treatments more efficiently.
Emerging Therapy Solutions
Venture Round in 2019
Emerging Therapy Solutions, Inc. is a company based in Bloomington, Minnesota, that specializes in the outsourced management of cell and gene therapy treatments for healthcare payers. Founded in 2018, it offers a comprehensive range of services including patient management, data collection, analysis, reporting, and claims administration. The company focuses on developing proprietary algorithms that enable effective targeting and segmentation of rare conditions. By providing a predictive intelligence platform, Emerging Therapy Solutions aims to simplify the management of complex therapy treatments, thereby enhancing the efficiency of healthcare providers in managing these advanced therapies.
Nimble Therapeutics
Series A in 2019
Nimble Therapeutics is a drug discovery company that leverages a maskless chemical synthesis platform to enable rapid, parallel synthesis and systematic discovery of novel medicines across therapeutic areas, including oral peptide therapeutics for immune-mediated diseases. The company aims to help researchers optimize molecules for improved drug-like properties and to identify treatments for diseases that are difficult to address with conventional therapies.
Invisalert Solutions
Venture Round in 2019
Invisalert Solutions, Inc. is a healthcare technology company that focuses on developing compliance-based patient safety solutions. Founded in 2011 and headquartered in Newtown Square, Pennsylvania, the company is known for its flagship product, ObservSMART. This innovative wristband features a software-based tracker that monitors observation compliance every 15 minutes, significantly reducing the risks of missed or falsified patient information. ObservSMART enhances communication among healthcare staff, provides proactive notifications for supervisory personnel, and offers access to comprehensive reports and analytics. By replacing traditional paper-based documentation, the system aims to improve compliance and patient care, particularly in psychiatric and emergency room settings. Invisalert Solutions specializes in addressing non-compliance issues across various sectors, including acute healthcare, corrections, drug delivery, long-term care, and youth and special education markets.
Teknova
Acquisition in 2019
Teknova specializes in supplying critical reagents for bioprocessing, bioproduction, and molecular diagnostics. Serving research, clinical, and applied markets, they offer standard catalog products and custom GMP items such as cell culture media, protein purification buffers, and molecular biology reagents. Known for agility and customer satisfaction, Teknova caters to complex formulation needs and provides rapid turnaround for custom GMP products.
Akoya Biosciences
Venture Round in 2018
Akoya Biosciences is a life sciences company specializing in spatial biology. It provides end-to-end solutions for high-parameter tissue analysis across discovery, translational research, and clinical applications, supporting the development of more precise therapies in immuno-oncology and other drug areas. The company offers two main platforms: PhenoCycler (formerly CODEX), a benchtop system capable of quantifying more than 40 biomarkers for biomarker discovery, and PhenoImager (formerly Phenoptics), an end-to-end multiplexed immunofluorescence platform designed for robust, high-throughput translational research and clinical trials. Its offerings include reagents, software, and services to enable tissue analysis and spatial phenotyping across the research continuum.
Precision NanoSystem
Series B in 2018
Precision Nanosystems specializes in the development of tools and processes for the creation and manufacturing of nanoparticles used in medicine and medical research. The company offers a range of products, including the NanoAssemblr benchtop instrument, which facilitates the prototyping of nanoparticles and the development of nanoparticle-based drugs that deliver RNA, small molecules, and protein therapeutics. Additionally, Precision Nanosystems provides various kits, such as Neuro9Kit for studying gene function in neurons and glial cells, Test9Kit for gene function studies in diverse cell types, and Hepato9Kit for liver gene function analysis. Their microfluidic devices enable the rapid and cost-effective manufacturing of lipid nanoparticles that can encapsulate and deliver bioactive agents, supporting life sciences researchers in developing innovative treatments and therapies for various diseases.
Carterra
Venture Round in 2018
Carterra, Inc. is a biotechnology company specializing in label-free biomolecular interaction analysis solutions. Founded in 2005 and headquartered in Salt Lake City, Utah, Carterra offers a range of products and services that facilitate multiplexing on planar array surfaces. Its flagship technologies include the MultipleX 96, an array-based surface plasmon resonance (SPR) imaging system, and the Continuous Flow Microspotter (CFM), a microarray printer that employs flow for efficient sample deposition. The company's offerings extend to contract research services, which cover high-throughput epitope binning and mapping, first-pass kinetics, and assay development. Additionally, Carterra provides a variety of supporting solutions, such as maintenance solutions, kits, and running buffers. These products are utilized in various applications, including kinetics software, epitope software, and antibody format development. Carterra also operates additional offices in Dublin, California; Andover, Massachusetts; and Munich, Germany, and sells its products through distributors in China and Japan, as well as online.
Aquaro Histology
Series A in 2017
Aquaro Histology, Inc. specializes in the manufacturing of a section mounting system designed to enhance the histology workflow in laboratories. Founded in 2017 and headquartered in Ann Arbor, Michigan, the company offers the Aquaro ASM, an automated solution that streamlines the placement of paraffin-embedded tissue sections onto slides. This compact and user-friendly unit is compatible with existing microtomes, improving workflow efficiency, section quality, and consistency. Aquaro Histology's products aim to support laboratory professionals in delivering better patient diagnoses and care.
RareCyte
Venture Round in 2017
RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.
Akoya Biosciences
Venture Round in 2017
Akoya Biosciences is a life sciences company specializing in spatial biology. It provides end-to-end solutions for high-parameter tissue analysis across discovery, translational research, and clinical applications, supporting the development of more precise therapies in immuno-oncology and other drug areas. The company offers two main platforms: PhenoCycler (formerly CODEX), a benchtop system capable of quantifying more than 40 biomarkers for biomarker discovery, and PhenoImager (formerly Phenoptics), an end-to-end multiplexed immunofluorescence platform designed for robust, high-throughput translational research and clinical trials. Its offerings include reagents, software, and services to enable tissue analysis and spatial phenotyping across the research continuum.
Dynex Technologies
Acquisition in 2017
Dynex Technologies, Inc. is a designer and manufacturer based in Chantilly, Virginia, specializing in fully automated ELISA microplate workstations, laboratory instruments, and related consumables and accessories. Established in 1952 and formerly known as Dynatech Laboratories, the company focuses on integrating advanced detection methods with automated sample handling to enhance laboratory efficiency. Dynex's products support scientists and clinicians in making significant discoveries and achieving more accurate diagnoses, ultimately contributing to improved health outcomes. The company distributes its offerings through a network of distributors across the United States, Canada, Mexico, South America, Asia, Europe, the Middle East, and Africa, as well as through online channels. In addition to its product range, Dynex Technologies also provides technical support services to its clients, addressing their evolving laboratory needs.
Medpricer
Venture Round in 2017
Medpricer develops a purchased services cost management solution tailored for the healthcare industry. The company's flagship platform, mSource, enables healthcare providers to discover, organize, benchmark, and manage their spending on service providers effectively. By offering precision benchmark reports, project management, and advisory services, Medpricer helps healthcare organizations enhance visibility and control over their expenses. This approach can lead to significant improvements in operating margins, with potential savings of up to 5%. Founded in 2004 and headquartered in Guilford, Connecticut, Medpricer also has an office in Walnut Creek, California. As of October 2019, it operates as a subsidiary of Premier, Inc.
TrakCel
Venture Round in 2016
TrakCel provides a cloud‑based platform that integrates and manages the entire supply chain for autologous and allogeneic cell and gene therapies. The system tracks program data, documents processes, and prepares regulatory audit materials, helping developers avoid the delays and costs of paper‑based workflows. It serves medical centers, logistics providers, manufacturers, and trial sponsors, and is used by both commercial and academic organizations to advance human health. Founded in 2012, the company is headquartered in Cardiff, United Kingdom.
Precision NanoSystem
Series A in 2015
Precision Nanosystems specializes in the development of tools and processes for the creation and manufacturing of nanoparticles used in medicine and medical research. The company offers a range of products, including the NanoAssemblr benchtop instrument, which facilitates the prototyping of nanoparticles and the development of nanoparticle-based drugs that deliver RNA, small molecules, and protein therapeutics. Additionally, Precision Nanosystems provides various kits, such as Neuro9Kit for studying gene function in neurons and glial cells, Test9Kit for gene function studies in diverse cell types, and Hepato9Kit for liver gene function analysis. Their microfluidic devices enable the rapid and cost-effective manufacturing of lipid nanoparticles that can encapsulate and deliver bioactive agents, supporting life sciences researchers in developing innovative treatments and therapies for various diseases.
RareCyte
Venture Round in 2012
RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.
PneumRx
Venture Round in 2011
PneumRx, Inc. is a medical device company focused on developing minimally invasive treatments for patients with emphysema. Established in 2004 and based in Mountain View, California, the company is known for its investigational device, the RePneu Lung Volume Reduction Coil, which aims to improve lung function in individuals suffering from this chronic condition.
Estech, founded in 1996 by Arthur and Raymond Bertolero, is a privately held medical device manufacturing and distribution company based in San Ramon, California. The company specializes in developing and marketing medical devices and disposables for cardiac surgery, with a focus on least invasive products. Estech's global distribution network and commitment to innovation have attracted top professionals in the medical device industry. The company's success is attributed to the extensive experience and dedication of its team, which has enabled it to thrive in the competitive medical device market.
AltheaDx, Inc. is a molecular diagnostics company based in San Diego, California, specializing in pharmacogenetics. The company utilizes an algorithm-based bioinformatics platform and a portfolio of pharmacogenetic testing products to assist healthcare providers in identifying the most suitable medications and dosage guidelines tailored to patients' genetic profiles and existing prescriptions. AltheaDx's IDgenetix test facilitates personalized therapeutic decisions for patients with common clinical conditions, including cardiovascular disease and neuropsychiatric disorders. Additionally, the company offers research and development services that encompass molecular biomarker discovery, assay development, and clinical trial testing, aimed at supporting diagnostic development for pharmaceutical, biotech, and medical device companies. AltheaDx serves a diverse range of clients, including long-term care facilities, government organizations, integrated delivery networks, and physicians. Founded in 1998, AltheaDx has established itself as a key player in the field of personalized medicine.
BioVentrix
Debt Financing in 2009
BioVentrix, Inc. is a medical device company based in San Ramon, California, that specializes in innovative treatments for congestive heart failure (CHF), particularly in patients with ischemic cardiomyopathy. Founded in 2003, the company has developed the Revivent Myocardial Anchoring System, which utilizes a hybrid closed-chest transcatheter procedure to enhance cardiac function. This device operates by restoring the size and volume of the left ventricle through the implantation of micro-anchoring pairs that effectively exclude scarred myocardium from healthy tissue. BioVentrix aims to provide less invasive, catheter-based solutions to improve patient outcomes and slow the progression of CHF, addressing a critical need in cardiac care.
Estech
Venture Round in 2009
Estech, founded in 1996 by Arthur and Raymond Bertolero, is a privately held medical device manufacturing and distribution company based in San Ramon, California. The company specializes in developing and marketing medical devices and disposables for cardiac surgery, with a focus on least invasive products. Estech's global distribution network and commitment to innovation have attracted top professionals in the medical device industry. The company's success is attributed to the extensive experience and dedication of its team, which has enabled it to thrive in the competitive medical device market.
Estech
Venture Round in 2008
Estech, founded in 1996 by Arthur and Raymond Bertolero, is a privately held medical device manufacturing and distribution company based in San Ramon, California. The company specializes in developing and marketing medical devices and disposables for cardiac surgery, with a focus on least invasive products. Estech's global distribution network and commitment to innovation have attracted top professionals in the medical device industry. The company's success is attributed to the extensive experience and dedication of its team, which has enabled it to thrive in the competitive medical device market.
Freedom Innovations LLC.
Funding Round in 2008
Freedom Innovations LLC specializes in the design and manufacture of prosthetic devices, focusing on lower limb solutions tailored for users with varying mobility levels, from low to high. The company offers a diverse range of prosthetic feet suitable for everyday walking and extreme sports, ensuring users can engage in a wide array of activities. Freedom Innovations collaborates closely with prosthetists and amputees to develop products that enhance the quality of life for individuals with disabilities, enabling them to lead more active and fulfilling lives.
Confirma is the only company that develops and markets an MRI-CAD system, CADstream, revolutionizing MRI study analysis and reporting through automated and standardized processing.
CADstream automates the analysis and interventional guidance of MRI studies, providing higher quality imaging studies, lower costs for radiology practices and improved communication tools for physicians and patients. CADstream can be integrated into any workflow scenario and is compatible with all MRI scanners and PACS.
Asuragen, Inc. is a molecular diagnostics company based in Austin, Texas, specializing in oncology and genetic disorders. Founded in 2005, the company develops and commercializes a diverse array of diagnostic products and services aimed at improving patient management. Its offerings include various AmplideX reagents for detecting genetic markers, as well as comprehensive cancer diagnostic kits, such as QUANTIDEX and Signature assays that target specific mutations and gene fusions. Asuragen employs its patented Armored RNA technology in its diagnostics portfolio, which encompasses genetic and oncology testing products alongside industry-leading controls. The company also provides GLP testing services and operates a cGMP manufacturing facility, ensuring a seamless process from discovery to commercialization. With a focus on enhancing treatment outcomes through precise data, Asuragen plays a critical role in the medical community's efforts to improve patient care in oncology and genetics.
AngioScore
Series E in 2007
AngioScore Inc. is a medical device company that specializes in the development, manufacturing, and marketing of innovative angioplasty catheters aimed at treating cardiovascular and vascular diseases. The company's flagship product, the AngioSculpt Scoring Balloon Catheter, is designed for use in both coronary and peripheral interventional markets. This device addresses the limitations of traditional angioplasty balloon catheters by integrating a semi-compliant balloon with a unique nitinol scoring element, enhancing the effectiveness of vascular interventions. AngioScore's focus on advancing endovascular therapy tools positions it as a key player in the medical device industry dedicated to improving patient outcomes in vascular treatments.
LDR Holding
Series C in 2007
LDR Holding Corporation is a medical device company specializing in the development and marketing of innovative implantable spine systems and instrumentation for surgical use. Founded in 2004 and headquartered in Austin, Texas, the company offers a diverse range of spinal surgery solutions, including cervical and lumbar artificial disc systems, pedicle screw systems, cervical cages, and synthetic bone substitutes, among others. LDR Holding's products are designed to address various spine disorders and are distributed through collaborations with surgeons and distributors in multiple countries, including Australia, Japan, and the United Kingdom. The company has expanded its global presence with additional offices in France, China, Brazil, and Germany, and it was formerly known as LDR Spine USA, Inc. prior to acquiring LDR Médical. LDR Holding is committed to advancing surgical technologies that enhance patient outcomes and support the surgeon community.
PneumRx, Inc. is a medical device company focused on developing minimally invasive treatments for patients with emphysema. Established in 2004 and based in Mountain View, California, the company is known for its investigational device, the RePneu Lung Volume Reduction Coil, which aims to improve lung function in individuals suffering from this chronic condition.
Ajinomoto Bio-Pharma Services
Series C in 2007
Ajinomoto Bio-Pharma Services is a contract development and manufacturing organization serving the pharmaceutical and biotechnology industries. It offers integrated preclinical through commercial development and cGMP manufacturing with aseptic fill-finish for small and large molecule APIs and intermediates. The company provides a broad platform portfolio, including Corynex protein expression technology, oligonucleotide synthesis, antibody-drug conjugations, high-potency APIs, biocatalysis, and continuous flow manufacturing. It also conducts gene expression analysis using eXpress Profiling technology and quantitative PCR testing, and performs drug product filling in vials and syringes as well as production of microbial-derived recombinant proteins and plasmid DNA.
Asuragen, Inc. is a molecular diagnostics company based in Austin, Texas, specializing in oncology and genetic disorders. Founded in 2005, the company develops and commercializes a diverse array of diagnostic products and services aimed at improving patient management. Its offerings include various AmplideX reagents for detecting genetic markers, as well as comprehensive cancer diagnostic kits, such as QUANTIDEX and Signature assays that target specific mutations and gene fusions. Asuragen employs its patented Armored RNA technology in its diagnostics portfolio, which encompasses genetic and oncology testing products alongside industry-leading controls. The company also provides GLP testing services and operates a cGMP manufacturing facility, ensuring a seamless process from discovery to commercialization. With a focus on enhancing treatment outcomes through precise data, Asuragen plays a critical role in the medical community's efforts to improve patient care in oncology and genetics.
AngioScore
Series D in 2006
AngioScore Inc. is a medical device company that specializes in the development, manufacturing, and marketing of innovative angioplasty catheters aimed at treating cardiovascular and vascular diseases. The company's flagship product, the AngioSculpt Scoring Balloon Catheter, is designed for use in both coronary and peripheral interventional markets. This device addresses the limitations of traditional angioplasty balloon catheters by integrating a semi-compliant balloon with a unique nitinol scoring element, enhancing the effectiveness of vascular interventions. AngioScore's focus on advancing endovascular therapy tools positions it as a key player in the medical device industry dedicated to improving patient outcomes in vascular treatments.
Accumetrics
Series B in 2004
Accumetrics is a privately-held company based in San Diego, California, that specializes in the development, manufacturing, and marketing of the VerifyNow System, a suite of assays designed to assess platelet function. Founded in 1996, Accumetrics initially sold to Radiometer in 2000, but was repurchased by its management and investors in 2003. The VerifyNow System allows for the measurement of individual responses to various antiplatelet agents, providing critical diagnostic instrumentation and test kits that support clinicians in personalizing antiplatelet therapy for improved patient outcomes.
Estech, founded in 1996 by Arthur and Raymond Bertolero, is a privately held medical device manufacturing and distribution company based in San Ramon, California. The company specializes in developing and marketing medical devices and disposables for cardiac surgery, with a focus on least invasive products. Estech's global distribution network and commitment to innovation have attracted top professionals in the medical device industry. The company's success is attributed to the extensive experience and dedication of its team, which has enabled it to thrive in the competitive medical device market.